Capivasertib + Abiraterone vs Placebo + Abiraterone in Patients with PTEN-Deficient #mHSPC: Updated Overall Survival from CAPItello-281. Presented by @fizazi_karim @GustaveRoussy.

UroToday.com· @urotoday · X·2026-10-24 06:15· 2 days agoScore70

Body · original

Capivasertib + Abiraterone vs Placebo + Abiraterone in Patients with PTEN-Deficient #mHSPC: Updated Overall Survival from CAPItello-281. Presented by @fizazi_karim @GustaveRoussy. #ESMO26 written coverage by @zklaassen_md > https://bit.ly/4iDxpio #ProstateCancer @myESMO

350 views · 2 likes · 4 reposts · 0 replies

Conference abstracts

LBA56NCT04746300matched by Rapid oral: Genitourinary tumours, prostate, penile and testis

Capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC): Updated overall survival (OS) from CAPItello-281

https://esmocongress.esmo.org

Source: UroToday.com · x.com